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A B S T R A C T
Background
Deep venous thrombosis (DVT) occurs in approximately one in 1000 adults every year, and has an annual mortality of 14.6%. In
particular, iliofemoral DVT can lead to recurrent thrombosis and post-thrombotic syndrome (PTS), a painful condition which can lead
to chronic venous insufﬁciency, oedema, and ulceration. It causes signiﬁcant disability, impaired quality of life, and economic burden.
Early thrombus removal techniques have been advocated in patients with an iliofemoral DVT in order to improve vein patency, prevent
valvular dysfunction, and reduce future complications, such as post-thrombotic syndrome and venous ulceration. One such technique
is pharmacomechanical thrombectomy, a combination of catheter-based thrombectomy and catheter-directed thrombolysis.
Objectives
To assess the effects of pharmacomechanical thrombectomy versus anticoagulation (alone or with compression stockings), mechanical
thrombectomy, thrombolysis, or other endovascular techniques in the management of people with acute DVT of the iliofemoral vein.
Search methods
The Cochrane Vascular Information Specialist searched the Specialised Register (last searched December 2015) and the Cochrane
Register of Studies (last searched December 2015). We searched clinical trials databases for details of ongoing or unpublished studies
and the reference lists of relevant articles retrieved by electronic searches for additional citations.
Selection criteria
Randomised controlled trials in which patients with an iliofemoral deep vein thrombosis were allocated to receive pharmacomechanical
thrombectomy versus anticoagulation, mechanical thrombectomy, thrombolysis (systemic or catheter directed thrombolysis), or other
endovascular techniques for the treatment of iliofemoral DVT.
Data collection and analysis
At least two review authors independently assessed studies identiﬁed for potential inclusion.
Main results
We found no randomised controlled trials that met the eligibility criteria for this review. We identiﬁed one ongoing study.
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Authors’ conclusions
There were no randomised controlled trials that assessed the effects of pharmacomechanical thrombectomy versus anticoagulation
(alone or with compression stockings), mechanical thrombectomy, thrombolysis, or other endovascular techniques in the management
of people with acute DVT of the iliofemoral vein that met the eligibility criteria for this review. Further high quality randomised
controlled trials are needed.
P L A I N L A N G U A G E S U M M A R Y
Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis
Background
Deep vein thrombosis (DVT) is a condition in which a blood clot forms in the deep vein of the leg or pelvis. It affects approximately 1
in 1000 people. If it is not treated, the clot can travel in the blood, and block the arteries in the lungs. This life-threatening condition
is called a pulmonary embolism and occurs in approximately 3 to 4 in 10,000 people. Another side-effect of DVT is post-thrombotic
syndrome (PTS), a condition in which the patient suffers pain, swelling, and changes in the skin of the leg, which can lead to an ulcer.
This causes signiﬁcant disability and diminished qualify of life, and is costly to the healthcare system.
One way to prevent another blood clot or PTS is to remove the clot. There are a number of ways to do this. A catheter can be inserted
into the vein and the clot removed directly (mechanical thrombectomy), the clot can be broken down through the use of drugs infused
into a vein in the foot or directly at the site of the clot using a catheter and X-ray control (pharmacomechanical thrombolysis), or
a combination of the two procedures. This review aimed to measure how safe and effective pharmacomechanical thrombectomy is,
compared to other techniques.
Key results
There were no randomised controlled trials that met the inclusion criteria of this review (current until December 2015). We identiﬁed
one ongoing study.
Quality of evidence
At present, there is a lack of randomised controlled trials that examine the comparative effectiveness and safety of pharmacomechanical
thrombectomy in the management of patients with DVT.
Conclusion
Further research is required before conclusions can be made.
B A C K G R O U N D
Description of the condition
Deep vein thrombosis (DVT) is a condition in which a blood clot
forms in the deep vein of the leg or pelvis. It is a commoncondition,
resulting in signiﬁcant morbidity and mortality.Deep vein throm-
bosis occurs in approximately one in 1000 adults annually (White
2003), and has an associated one year mortality of 14.6% (Ageno
2006). In particular, untreated proximal DVT or iliofemoral DVT
carries an approximate 50% risk of developing into a symptomatic
pulmonary embolism within three months, 10% of which carries
a risk of mortality within one hour of symptom onset (Kearon
2003). A major cause of DVT-related morbidity is post-throm-
botic syndrome (PTS), which is characterised by pain, chronic
venous insufﬁciency, oedema, and associated skin changes, and
can progress to venous ulceration, despite conventional treatment.
Post-thrombotic syndrome typically occurs within two years of a
DVT, and is reported to occur in around 30% to 60% of patients,
with 10% suffering from severe PTS (Prandoni 2009). It causes
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signiﬁcant disability, impaired quality of life and economic burden
(Access Economics Pty Limited 2008).
Deep vein thrombosis can be divided anatomically, into proximal
DVT, affecting either the iliofemoral or femoral vein and distal
DVT, affecting the popliteal vein or more distally (Jenkins 2011).
Iliofemoral DVT occludes both draining venous systems of the
lower limb, that of the femoral vein and the superﬁcial femoral
vein, so there is decreased room for collateralisation of venous
drainage (Jenkins 2011). Consequently, iliofemoral DVT has an
increased propensity for complications such as pulmonary em-
bolism and PTS, compared to popliteal DVT.
Standard treatment of DVT currently involves immediate in-
travenous anticoagulation with unfractionated heparin, or more
recently, with the use of low molecular weight heparin (Merli
2008). Early ambulation and graduated compression stockings
(30 mmHg to 40 mmHg) are also standard treatment and have
been shown to be particularly effective in preventing the develop-
ment of PTS (Musani 2010). A meta-analysis indicated a 0.54 rel-
ative risk reduction in PTS with the use of graduated compression
stockings post-DVT(Musani 2010). A randomised controlled trial
by Prandoni 2004 determined that the incidence of PTS in the
control group versus the elastic stockings group was 40.0% ver-
sus 21.1% after six months, 46.7% versus 22.2% after one year,
and 49.1% versus 24.5% after two years. However, the SOX trial,
a randomised placebo-controlled trial, showed that stockings of-
fered no beneﬁt in the prevention of PTS (Kahn 2014).
The goal of this current treatment strategy is to prevent throm-
bus propagation, embolisation, and recurrence of venous throm-
boembolism during both the early and later course of the disease.
However, anticoagulation lacks ﬁbrinolytic activity, so there is no
attempt to remove or reduce existing thrombus load. In ultra-
sound based studies, complete resolution of DVT at one year was
only around 50% (Kearon 2003). Furthermore, the one-year in-
cidence of PTS is around 25% following ﬁrst-time DVT, despite
treatment with anticoagulation and elastic compression bandages
(Pappy 2010).
IliofemoralDVT inparticular, carries a signiﬁcant risk of both PTS
and recurrent venous thromboembolism. Therefore, early throm-
bus removal techniques have been advocated in these select pa-
tient groups, in order to improve vein patency, preventing valvular
dysfunction, and reduce future complications, such as PTS and
venous ulceration.
Description of the intervention
Mechanical thrombectomy
Thrombectomy forDVTcanbe performed through either an open
surgical approach or a percutaneous endovascular approach. Open
thrombectomy is reserved for life- or limb-threatening DVT, and
is seldom used, as it is much more invasive than endovascular tech-
niques, and is associated with a disproportionately high incidence
of rethrombosis (Suwanabol 2013).
Percutaneousmechanical thrombectomymodalities are a relatively
new intervention available for treating DVT (Jenkins 2011). A
number of different percutaneous devices exist, however, they all
reduce clot burden through either suction, rotation, rheolysis, ul-
trasound, or a combination there-of.
Pharmacological thrombolysis
Thrombolysis has been used as a technique to remove clot bur-
den, and can either be performed systemically, or locally in a
procedure called catheter-directed thrombolysis (Jenkins 2011).
Systemic thrombolysis has been shown to enhance clot removal
and prevent propagation of thrombosis. However, it carries an in-
creased risk of major bleeding episodes, and therefore, is rarely
used in the setting of an acute DVT. Catheter-directed thrombol-
ysis is a percutaneous technique involving the delivery of throm-
bolytics by an infusion catheter, directly to the venous thrombus,
which allows clot lysis, whilst avoiding themajor bleeding risks as-
sociated with systemic thrombolysis. Randomised controlled tri-
als have demonstrated the feasibility and effectiveness of the tech-
nique in reducing PTS whilst minimising major bleeding risks to
1.7%, compared to 2% in the use of anticoagulation-only groups
(Enden 2009; Watson 2014).
Pharmacomechanical thrombectomy
Some medical devices combine the use of both percutaneous
mechanical thrombectomy and thrombolysis, using the same
endovascular techniques. This combination of catheter-based
thrombectomy and catheter-directed thrombolysis is referred to
as pharmacomechanical thrombectomy.
Pharmacomechanical thrombectomy, when compared to catheter-
directed thrombolysis alone, has been shown to result in similar
levels of clot removal, but with signiﬁcant reduction in use of
hospital resources, catheterisation, infusion time, and total dose of
thrombolytic, hence, potentially reducing adverse bleeding events
as well (Jenkins 2011).
Percutaneous endovenous intervention refers to a variety of en-
dovascular techniques used for thrombus removal. It includes any
one or more endovascular techniques, such as thrombectomy, bal-
loon venoplasty, stenting, and low-dose thrombolysis, and has
been shown to reduce DVT and PTS recurrence (TORPEDO
2012).
How the intervention might work
Evidence suggests that early removal of the thrombus with throm-
bolysis can reduce the incidence of post-thrombotic syndrome,
and improve venous haemodynamics (Elliot 1979; Plate 1990;
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Turpie 1990). In addition, mechanical thrombectomy facilitates a
more rapid removal of the thrombus, improving venous patency,
decreasing venous hypertension, and ultimately, preventing valvu-
lar dysfunction and the development of PTS (Suwanabol 2013).
Combining both mechanical thrombectomy with thrombolysis in
pharmacomechanical thrombectomy can reduce the required dose
of thrombolytic agent used compared to a thrombolytic technique
alone, reducing the bleeding risks associated with either catheter-
directed thrombolysis or systemic thrombolysis, whilst conferring
the immediate beneﬁts of a mechanical reduction in clot load
(Jenkins 2011).
Why it is important to do this review
In addition to anticoagulation, thrombectomy, catheter-directed
thrombolysis and pharmacomechanical thrombectomy are used
as techniques to prevent thrombus propagation and thrombus re-
moval, and to decrease the risk of both pulmonary embolism and
PTS (Jenkins 2011). This review examined the evidence support-
ing the use of pharmacomechanical thrombectomy for iliofemoral
DVT.
O B J E C T I V E S
To assess the effects of pharmacomechanical thrombectomy versus
anticoagulation (alone or with compression stockings), mechani-
cal thrombectomy, thrombolysis, or other endovascular techniques
in the management of people with acute deep vein thrombosis of
the iliofemoral vein.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered randomised controlled trials (RCTs) that com-
pared pharmacomechanical thrombectomy versus anticoagulation
(alone or in combination with compression stockings), mechan-
ical thrombectomy, thrombolysis (systemic or catheter-directed
thrombolysis), or other endovascular techniques for the treatment
of iliofemoral deep vein thrombosis (DVT).
Types of participants
We included patients of all ages with DVT conﬁrmed by objective
testing, such as venography or duplex ultrasonography. We only
considered DVTs at the iliofemoral level. We excluded patients
with recurrent venous thromboembolism (VTE) or post-throm-
botic syndrome (PTS), and those with treatment commencing af-
ter 21 days. If we were unable to clarify the anatomical level of
DVT after interrogation of the data in a study, we did not use the
results in our data analysis.
Types of interventions
We included any pharmacomechanical thrombectomy, deﬁned as
a combination of locally delivered thrombolytic agent used in con-
junction with mechanical thrombectomy. Patients who received
any type of thrombolysis or thrombectomy intervention also re-
ceived standard DVT management, which included anticoagula-
tion and the use of compression stockings.
We considered the following comparisons:
• pharmacomechanical thrombectomy versus anticoagulation
alone;
• pharmacomechanical thrombectomy versus anticoagulation
and compression stocking use;
• pharmacomechanical thrombectomy versus mechanical
thrombectomy;
• pharmacomechanical thrombectomy versus thrombolysis;
• pharmacomechanical thrombectomy versus other
endovascular techniques (including balloon venoplasty and
stenting).
Types of outcome measures
For all outcomes, we had planned to collect data for an early (up to
one month), intermediate (one month to two years), and a long-
term period (more than two years).
Primary outcomes
1. Post-thrombotic syndrome: (including venous ulceration
rates, as deﬁned by the Villalta scale; Prandoni 1992)
2. Any improvement in venous patency (assessed by objective
measures, such as venography, where pre- and post-comparative
data on the degree of restoration of the lumen were available)
3. Major bleeding (as deﬁned by the International Society on
Thrombosis and Haemostasis (ISTH); Schulman 2005):
i) Fatal bleeding
ii) Symptomatic bleeding in a critical area or organ, such
as intracranial, intraspinal, intraocular, retroperitoneal, intra-
articular or pericardial, or intramuscular with compartment
syndrome
iii) Bleeding causing a fall in haemoglobin level of 20 g/L
(1.24 mmol/L) or more, or leading to transfusion of two or more
units of whole blood or red cells
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iv) Any combination of points a to c
Secondary outcomes
1. Recurrent DVT
2. Pulmonary embolism
3. Mortality (all cause and pulmonary embolism-related)
4. Stroke, in particular, haemorrhagic stroke (preferably
documented by objective means such as a computerised
tomography (CT) scan or autopsy
5. Venous function (assessed by duplex ultrasound or other
objective means, such as foot volumetry or ambulatory venous
pressure measurements)
6. Time in hospital
7. Quality of life
Search methods for identification of studies
Electronic searches
The Cochrane Vascular Information Specialist (CIS) searched the
following databases for relevant trials:
• The Cochrane Vascular Specialised Register (December
2015);
• The Cochrane Central Register of Controlled Trials
(CENTRAL (2015, Issue 11)) via The Cochrane Register of
Studies Online.
See Appendix 1 for details of the search strategy used to search
CENTRAL.
The Cochrane Vascular Specialised Register is maintained by the
CIS and is constructed from weekly electronic searches of MED-
LINEOvid, EmbaseOvid, CINAHL, AMED, and through hand-
searching relevant journals. The full list of the databases, jour-
nals, and conference proceedings that have been searched, and the
search strategies used, are described in the Specialised Register sec-
tion of the Cochrane Vascular module in the Cochrane Library (
www.cochranelibrary.com).
The CIS also searched the following trial databases for details of
ongoing and unpublished studies, using the terms thrombectomy
and thrombosis:
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) Search Portal (apps.who.int/
trialsearch/);
• ClinicalTrials.gov (clinicaltrials.gov/);
• ISRCTN Register (www.isrctn.com/)
Searching other resources
We searched citations within identiﬁed studies. We also contacted
authors of relevant papers by email, to identify any unpublished
RCTs.
Data collection and analysis
Selection of studies
Two review authors (LR and AB or OM) independently reviewed
the results of all searches and identiﬁed any article that was eligi-
ble, given a reference to thrombectomy for DVT. The two review
authors discussed each study to conﬁrm eligibility for inclusion
in the systematic review; those that did not fulﬁl the criteria as
described in Criteria for considering studies for this review were
excluded, and the reasons for exclusion were described in the re-
view. Disagreements were resolved by consensus.
Data extraction and management
Two review authors (LR, AB) had intended to independently ex-
tract from each study, information about the study characteristics,
participants, interventions, duration of follow-up, and outcome
parameters, using standardised forms.Where available, we had in-
tended to extract data on the following items:
1. Study design.
2. Quality items.
3. Number of study patients.
4. Participants, including: age, sex, length of clot, diagnosis
(clinical or ultrasound), presence of pulmonary embolism prior
to treatment, presence of phlegmasia, and co-morbidities.
5. Interventions, including: thrombectomy device used,
adverse events (major and minor), dose and delivery of
thrombolytics, length of stay in hospital, and veins treated.
6. Outcome measures, including: PTS, venous patency and
valve competency, major bleeding, recurrent DVT, pulmonary
embolism, mortality, stroke, venous function, time in hospital,
and quality of life.
7. Length of follow-up.
Assessment of risk of bias in included studies
Two review authors (LR, AB) had intended to independently assess
the design and execution of each study according to the follow-
ing criteria: random sequence generation, allocation concealment
of treatment, blinding of participants, personnel, and outcomes,
incomplete outcome data, selective outcome reporting, and other
sources of bias in accordance with Cochrane’s tool for assessing
risk of bias (Higgins 2011). We had intended to judge the studies
as either low risk of bias, high risk of bias or, unclear (due to either
lack of information or uncertainty over the potential for bias). We
had planned to resolve disagreements by consensus between the
two review authors, and involve a third review author (OM) if
necessary.
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Measures of treatment effect
Wehad intended to assess dichotomous data using risk ratio (RRs)
with 95% conﬁdence intervals (CIs). We had planned to analyse
continuous outcomes using mean difference (MDs) with 95%CIs
where the scales were the same, and where scales were different
but outcome measured was the same, we had planned to use the
standardised mean difference (SMD) with 95% CIs.
Unit of analysis issues
We did not include cross-over trials. The individual patient was
the unit of the analysis.
Dealing with missing data
Where information was missing, we had planned to contact the
authors of the relevant study. If unsuccessful, we had intended
to exclude the data from the meta-analysis, but report it in the
review.We had planned to include outcomemeasures only if it had
been the intention of the study authors to perform the necessary
assessments in all randomised patients. If less than 50% of the
patients in a study had an acceptable follow-up for a particular
outcome measure, due to the associated high risk of attrition bias,
we had planned to not report the results of this outcome measure.
Assessment of heterogeneity
If the included studies were comparable with regard to age, sex,
treatment, and outcome deﬁnitions, we had planned to perform a
pooled analysis. We had intended to assess heterogeneity with the
use of forest plots and by a formal statistical test for heterogeneity,
i.e. the I² statistic. Substantial heterogeneity was deﬁned as I²
greater than 50% (Higgins 2011). We had planned to explore
possible causes of heterogeneity, and take appropriate measures.
Assessment of reporting biases
If more than ten studies had been included in a meta-analysis, we
had planned to construct a funnel plot to graphically ascertain the
existence of publication bias (Higgins 2011).
Data synthesis
We had planned to enter data into the Cochrane software, Review
Manager 2014, and analyse them according to the guidelines in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011).We had intended to use a ﬁxed-effect model if we found no
substantial heterogeneity, and a random-effects model if we found
heterogeneity (I² greater than 50%).
Subgroup analysis and investigation of heterogeneity
We had planned to perform subgroup analysis based on systemic
thrombolysis and catheter-directed thrombolysis, to determine the
effect it may have had on outcome and possible heterogeneity
between studies. We also had intended to examine heterogeneity
for these by visual inspection of forest plots and the I² statistic.
Sensitivity analysis
We had planned to perform a sensitivity analysis by excluding
studies that were at high risk of bias.
Summary of findings
We had planned to present the main ﬁndings of the review results
concerning the quality of evidence, the magnitude of effect of the
interventions examined, and the sum of available data on the pri-
mary outcomes (Types of outcome measures) in a ’Summary of
ﬁndings’ table, according to the GRADE principles as described
by Higgins 2011 and Atkins 2004. Since we had planned to as-
sess different comparisons of interventions, we had planned to de-
velop a ’Summary of ﬁndings’ table for each comparison using the
GRADEpro (GRADEproGDT) software to assist in the prepara-
tion of the ’Summary of ﬁndings’ table.
R E S U L T S
Description of studies
Results of the search
See Figure 1
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Figure 1. Study flow diagram.
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Included studies
We found no randomised controlled trials that met the eligibility
criteria for this review.
Excluded studies
See Characteristics of excluded studies
We excluded two studies. One study examined percutaneous
aspiration thrombectomy versus medical treatment only (Cakir
2014), and the second study was not a randomised controlled trial
(Srinivas 2014).
Ongoing studies and studies awaiting classification
We identiﬁed one eligible ongoing study (NCT02414802). This
study is currently enrolling participants.
We identiﬁed one study that appeared tomeet the inclusion criteria
(TORPEDO2012).However, on examination of the TORPEDO
2012 trial, it was clear that not all patients had an iliofemoralDVT,
and not all were treated with pharmacomechanical thrombec-
tomy. We contacted the authors of this trial to obtain the data
on iliofemoral DVT patients stratiﬁed by pharmacomechanical
thrombectomy, but to date, we have not had a response. If ob-
tained, we hope to include this data in future updates of this re-
view.
Risk of bias in included studies
As we identiﬁed no eligible completed studies, it was not possible
to assess risk of bias.
Effects of interventions
We found no randomised controlled trials that met the eligibility
criteria for this review.
D I S C U S S I O N
Summary of main results
We found no randomised controlled trials investigating the ef-
fects of pharmacomechanical thrombectomy versus anticoagula-
tion (alone or with compression stockings), mechanical thrombec-
tomy, thrombolysis, or other endovascular techniques in the man-
agement of people with acute deep venous thrombosis (DVT) of
the iliofemoral vein that met the eligibility criteria for this review.
Overall completeness and applicability of
evidence
We found no randomised controlled trials that met the eligibility
criteria for this review.
At present, there is a lack of randomised controlled trials on the
effectiveness and safety of pharmacomechanical thrombectomy in
the management of people with iliofemoral DVT.
Quality of the evidence
We found no randomised controlled trials that met the eligibility
criteria for this review; therefore, we were unable to assess the
quality of the evidence.
Potential biases in the review process
None of the review authors have any commercial or other conﬂict
of interest. The Cochrane Vascular Information Specialist per-
formed a comprehensive search of the literature, and review au-
thors selected studies in accordance with recommendations pro-
vided in the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011). We resolved disagreements by discussion.
Agreements and disagreements with other
studies or reviews
To date, no other systematic review has examined pharmacome-
chanical thrombectomy for the management of people with acute
DVT of the iliofemoral vein.
One study compared the effectiveness of catheter-directed throm-
bolysis in conjunction with assisted mechanical thrombolysis
versus routine anticoagulation (unfractionated or low molecular
weight heparin) in patients with a lower limb DVT (Srinivas
2014). The study was not included in this review as it was not ran-
domised. Results showed that after sixmonths, iliofemoral patency
was found in 20 out of 25 patients (80%) in the intervention group
versus seven out of 26 patients (23%) treated with anticoagula-
tion alone (P < 0.01). Post-thrombotic syndrome was diagnosed
in 5 patients (20%) in the intervention group versus 19 (77%) in
the anticoagulation alone group (P < 0.01). Pulmonary embolism
occurred in 4 patients (15%) in the intervention group versus 6
(21%) of the patients who received anticoagulation. Death due to
pulmonary embolism occurred in two patients in each treatment
group. In the intervention group, 4 patients (15%) also devel-
oped anaemia, and required a blood transfusion. There was no dif-
ference in prolonged hospital stay between the catheter-directed
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thrombolysis in conjunction with assisted mechanical thrombol-
ysis group (mean 5 days, standard deviation (SD) 1.3 days) and
the routine anticoagulation arm (mean 4.8 days, SD 1.4 days).
A recent review discussed the three main types of pharmacome-
chanical thrombectomy devices (rotating motorised systems, rhe-
olytic instruments and ultrasound enhanced devices; Blackwood
2016). The devices were compared for success rate, clinical pa-
tency at follow-up, and complications, based on 3077 participants
in seven studies. The studies varied in size from 40 to 2204 partici-
pants. Patency rates varied from65%to98%,major bleeding com-
plications ranged from 0% to 11%, and the rate of post-throm-
botic syndrome ranged from 3% to 48%. However, the quality of
the studies was extremely varied. Only two randomised controlled
trials were included, only one of which appeared to meet the in-
clusion criteria for this review (TORPEDO 2012). However, on
examination of the TORPEDO 2012 trial, it was clear that not
all patients had an iliofemoral DVT, and not all were treated with
pharmacomechanical thrombectomy.We contacted the authors of
this trial to obtain the data on iliofemoral DVT patients stratiﬁed
by pharmacomechanical thrombectomy but, to date, we have not
had a response. If obtained, we hope to include this data in future
updates of this review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufﬁcient evidence to draw any conclusions about effec-
tiveness and safety of pharmacomechanical thrombectomy versus
anticoagulation (alone or with compression stockings), mechani-
cal thrombectomy, thrombolysis, or other endovascular techniques
in the management of people with acute deep venous thrombosis
of the iliofemoral vein, because no randomised trials were eligible
for inclusion in this review.
Implications for research
This review highlights the gap in evidence for the use of phar-
macomechanical thrombectomy for acute deep venous thrombo-
sis (DVT) of the iliofemoral vein. Future randomised controlled
trials are required. Future studies should also aim to incorporate
the Lower Extremity Thrombosis (LET) score (Strijkers 2015), a
relatively new classiﬁcation system designed to identify patients at
high risk for developing post-thrombotic syndrome in the acute
DVT phase, using thrombus location and extent.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cakir 2014 Study examined percutaneous aspiration thrombectomy versus medical treatment only
Srinivas 2014 Study was not a randomised trial (personal communication with the author)
Characteristics of studies awaiting assessment [ordered by study ID]
TORPEDO 2012
Methods Study design: randomised controlled trial
Participants Setting: hospital
Country: United States of America
Inclusion criteria: adult patients with symptomatic DVT, involving popliteal vein or more proximal venous segments,
diagnosed by venous duplex sonography or multislice CT venography. The affected veins were divided into ﬁve
segments, based on the anatomical involvement of DVT: inferior vena cava (IVC), right and left iliac veins, and right
and left femoropopliteal veins
Exclusion criteria: patients were excluded if they had serious bleeding in the previous 4 weeks, contra-indication to
unfractionated or low-molecular weight heparin, or severe thrombocytopaenia (platelet count of < 30,000/mm³)
Interventions Intervention 1: PEVI + anticoagulation. For acute DVT with otherwise preserved venous anatomy, thrombectomy
was performed using any of the following: Angiojet DVX catheter (Medrad/Possis, Warrendale, PA), Trellis device
(Bacchus Vascular, Santa Clara, CA), or manual aspiration with an 8-F guide catheter. No preference was given to any
thrombectomy device, and its use was based on operator discretion and device availability. For severe ’venosclerotic’
disease with distorted anatomy, a venous conduit was created using balloon venoplasty and stents. If residual thrombus
was more than 30% of the luminal area, an infusion catheter was placed and low-dose thrombolytic therapy with
tissue plasminogen activator (tPA) at 1 mg/hr delivered for 20 to 24 hr. In this scenario, the patient was brought back
to the angiography suite for re-evaluation after tPA administration
Intervention 2: anticoagulation alone. Initial anticoagulation therapy consisted of subcutaneous enoxaparin at 1
mg/kg twice daily, administered subcutaneously. For those with renal insufﬁciency or concomitant massive PE,
unfractionated heparin (UFH) was started at 80 IU/kg intravenously as loading dose, followed by 18 IU/hr, with
subsequent adjustments to keep the activated partial thromboplastin time 1.5 to 2 times the baseline level. Warfarin
was initiated on admission
Outcomes Primary: post-thrombotic syndrome and recurrence of VTE at 6 months
Secondary: bleeding, duration of hospitalisation, reduction of leg oedema, reduction of skin induration, and patient’s
subjective perception of improvement
Notes Authors were contacted for data on participants with iliofemoral DVT and for data stratiﬁed by pharmacomechanical
thrombectomy. To date, no response has been received
CT: computed tomography
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DVT: deep vein thrombosis
PE: pulmonary embolism
PEVI: percutaneous endovenous intervention
VTE: venous thromboembolism
Characteristics of ongoing studies [ordered by study ID]
NCT02414802
Trial name or title Study on the application of a novel aspiration thrombectomy device combined with catheter-directed throm-
bolysis for the treatment of acute iliofemoral deep venous thrombosis
Methods Study design: randomised, parallel assignment study
Participants Setting: hospital
Country: China
Inclusion criteria:
• clinical diagnosis of iliofemoral deep venous thrombosis
• symptoms of less than 14 days’ duration
• good function status
• a life expectancy of more than 1 year
• a low risk of bleeding
Exclusion criteria:
• without iliac vein thrombosis
• anticoagulation or thrombolysis contraindications, or both
• systemic infection
• heart, hepatic, renal function insufﬁciency
Interventions Intervention 1: combined thrombectomy device. Amanual spiral thrombus broken suction device will be used
for thrombectomy before catheter-directed thrombolysis. Ten million U of urokinase once every 4 to 6 hours
will be used during catheter-directed thrombolysis therapy. Anticoagulation therapy will be administered via
subcutaneous injection of low molecular weight heparin calcium (LMWH-Ca 5000 U/12 h) at discharge
Intervention 2: participants will undergo catheter-directed thrombolysis alone. A total of 100,000 units
urokinase will be pulse-spray injected through the catheter once every 4 to 6 hours. Anticoagulation therapy
will be administered via subcutaneous injection of LMWH-Ca 5000 U/12 h at discharge
Outcomes Primary: patency of lower extremity deep venous system
Secondary: technical success rate, thrombus removal rate, complications, blood loss, improvement of clinical
symptoms and signs and incidence of post-thrombotic syndrome
Starting date December 2014
Contact information Qingqiao Zhang, Xuzhou Medical College
Notes
LMWH-Ca: low molecular weight heparin calcium
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MESH DESCRIPTOR Thrombosis 1231
#2 MESH DESCRIPTOR Thromboembolism 892
#3 MESH DESCRIPTOR Venous Thromboembolism 233
#4 MESHDESCRIPTOR Venous Thrombosis EXPLODE ALL
TREES
1996
#5 (thrombus* or thrombopro* or thrombotic* or thrombolic*
or thromboemboli* or thrombos* or embol*):TI,AB,KY
16760
#6 MESH DESCRIPTOR Pulmonary Embolism EXPLODE
ALL TREES
729
#7 (PE or DVT or VTE):TI,AB,KY 4422
#8 ((vein* or ven*) near thromb*):TI,AB,KY 6043
#9 (blood near3 clot*):TI,AB,KY 2424
#10 (pulmonary near3 clot*):TI,AB,KY 5
#11 (lung near3 clot*):TI,AB,KY 4
#12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR
#9 OR #10 OR #11
21706
#13 MESH DESCRIPTOR Thrombectomy EXPLODE ALL
TREES
143
#14 (percutaneous near2 endovascular):TI,AB,KY 13
#15 PEVI:TI,AB,KY 4
#16 thrombecto*:TI,AB,KY 428
#17 excis* 3652
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(Continued)
#18 suction:TI,AB,KY 1970
#19 aspiration or thromboaspirat* 3693
#20 angiojet:TI,AB,KY 10
#21 jet*:TI,AB,KY 756
#22 pharmaco*:TI,AB,KY 122292
#23 mechanical*:TI,AB,KY 11751
#24 (Trerotola OR Rotarex or Aspirex):TI,AB,KY 3
#25 (amplatz OR angiovac):TI,AB,KY 26
#26 rotat*:TI,AB,KY 4215
#27 rheoly*:TI,AB,KY 26
#28 ultrasound:TI,AB,KY 11469
#29 Endowave:TI,AB,KY 0
#30 (power near2 pulse):TI,AB,KY 20
#31 #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR
#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR
#27 OR #28 OR #29 OR #30
154857
#32 #12 AND #31 5175
C O N T R I B U T I O N S O F A U T H O R S
LR: drafted the protocol, selected studies for inclusion and wrote the review
OM: contributed to the protocol, selected studies for inclusion, and provided clinical input to the review
AB: drafted the protocol, selected studies for inclusion
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D E C L A R A T I O N S O F I N T E R E S T
LR: none known
OM: none known
AD: none known
S O U R C E S O F S U P P O R T
Internal sources
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External sources
• National Insitute for Health Research (NIHR), UK.
This project was supported by the NIHR, via Cochrane Programme Grant funding (13/89/23) to Cochrane Vascular. The views and
opinions expressed therein are those of the review authors and do not necessarily reﬂect those of the Systematic Reviews Programme,
NIHR, NHS or the Department of Health.
• Chief Scientist Ofﬁce, Scottish Government Health Directorates, The Scottish Government, UK.
The Cochrane Vascular editorial base is supported by the Chief Scientist Ofﬁce.
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